Jia Junhai, Sun Yue, Ren Jingjie, Li Muyang, Wang Jiancheng, Li Haiyang
Gansu Province Hospital Rehabilitation Center.
School of Nursing, Lanzhou University.
Medicine (Baltimore). 2019 Jul;98(30):e16517. doi: 10.1097/MD.0000000000016517.
Prostate cancer (PCa) is common, with it being the 2nd most prevalent cancer in men worldwide and the 6th leading cause of death in men. Screening for any type of cancer aims to increase the chances of successful treatment through early detection of the disease. There were some systematic reviews (SRs) evaluated the diagnostic value of biomarkers for the diagnosis of PCa and no studies have been conducted to analyze the quality of these SRs. We are not clear which kind of marker is the best choice. Thus, this study aims to assess the methodologic quality of the SRs and reanalyze the published data based on SRs for the biomarkers to find the optimal biomarker for the early diagnosis of PCa.
We performed a systematic literature search of PubMed, Embase, Web of Science, and Cochrane Library and to identify relevant SRs from inception to April 2019. Diagnostic accuracy studies included any type of single biomarker or combined biomarkers aimed at evaluating the diagnostic value is considered eligible for this overview. The Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) instrument will be used to evaluate the risk of bias of the included SRs. Standard pairwise meta-analysis and adjusted indirect comparison will be used to compare the diagnostic value of different biomarkers.
The results of this study will be submitted to a peer-reviewed journal for publication.
This study will reanalyze the published data based on SRs. We hope that the results will help find a biomarker with the superior diagnostic performance for the diagnosis of PCa.
CRD42019125880.
前列腺癌（PCa）很常见，是全球男性中第二大常见癌症，也是男性第六大死因。任何类型癌症的筛查旨在通过早期发现疾病来增加成功治疗的机会。有一些系统评价（SRs）评估了生物标志物对前列腺癌诊断的价值，但尚未有研究分析这些SRs的质量。我们不清楚哪种标志物是最佳选择。因此，本研究旨在评估SRs的方法学质量，并基于SRs重新分析已发表的生物标志物数据，以寻找用于前列腺癌早期诊断的最佳生物标志物。
我们对PubMed、Embase、Web of Science和Cochrane图书馆进行了系统的文献检索，以识别从创刊到2019年4月的相关SRs。诊断准确性研究包括任何类型的旨在评估诊断价值的单一生物标志物或联合生物标志物，均被认为符合本综述的要求。将使用多重系统评价评估-2（AMSTAR-2）工具来评估纳入的SRs的偏倚风险。将使用标准的成对荟萃分析和调整后的间接比较来比较不同生物标志物的诊断价值。
本研究结果将提交给同行评审期刊发表。
本研究将基于SRs重新分析已发表的数据。我们希望结果将有助于找到一种具有卓越诊断性能的生物标志物用于前列腺癌的诊断。
PROSPERO注册号：CRD42019125880。
